Hopec Pharma is developing UPEC-FimON, a first-in-class immunotherapy for non-muscle invasive bladder cancer (NMIBC). This novel treatment utilizes a genetically modified E. coli bacterium to specifically target and eliminate bladder cancer cells. The company aims to provide safe, effective, and accessible therapeutic innovation for NMIBC patients globally.
Funding
Funding not disclosed
Founders
Product
Problem
Non-muscle-invasive bladder cancer (NMIBC) requires more effective and patient-friendly treatment options. Current treatments often have limited efficacy or significant side effects, creating a need for innovative therapeutic approaches.
Solution
Hopec Pharma is developing UPEC-FimON, an immunotherapy that utilizes genetically modified uropathogenic E. coli (E. coli) to selectively target and eliminate NMIBC cells. This innovative approach aims to improve treatment outcomes while enhancing patient comfort. By leveraging cutting-edge science and strategic global partnerships, Hopec Pharma seeks to deliver therapies that surpass existing options and redefine the future of bladder cancer care. UPEC-FimON represents a significant advancement in cancer therapy, offering a novel mechanism for targeting and eradicating bladder cancer cells.
Target Audience
The primary target audience includes patients diagnosed with non-muscle-invasive bladder cancer and the healthcare providers who treat them, such as oncologists and urologists.
Features
- Genetically modified uropathogenic E. coli (UPEC) for targeted delivery to bladder cancer cells
- Immunotherapy approach to stimulate the patient's immune system against cancer
- Selective targeting of non-muscle-invasive bladder cancer cells
- GMP-certified production through partnership with Scinai Immunotherapeutics
- Phase 1 multicenter trials planned for Q2 2025 at Hadassah and Sheba medical centers
- Research in immune mechanisms via single-cell RNA-seq studies